SillaJen IPO Priced Low But Hopes High As Pexa-Vec Progresses
Executive Summary
SillaJen, a South Korean venture that has been under investors' radars, is set to float at the lower end of its range as investors focus on the potential of its lead asset Pexa-Vec for liver cancer.
You may also be interested in...
Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Need To Redefine Recipe For Success In Korean Biotech?
In South Korea, success and failure in the bioventure sector seems to be measured differently to elsewhere, while other legal and investment hurdles remain, and some experts are now pointing to the need for change if the industry is to move on to the next phase.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.